Top

Published in:

01-11-2011 | Gastrointestinal Oncology

Minimally Invasive Esophagectomy is Safe and Effective Following Neoadjuvant Chemoradiation Therapy

Authors: Kfir Ben-David, MD, George Rossidis, MD, Robert A. Zlotecki, MD, PhD, Stephen R. Grobmyer, MD, Juan C. Cendan, MD, George A. Sarosi, MD, Steven N. Hochwald, MD

Published in: Annals of Surgical Oncology | Issue 12/2011

Abstract

Background

Minimally invasive esophagectomy (MIE) is technically demanding, and implementation has been hindered by a steep learning curve. Despite widespread concern about the successful performance of this procedure following neoadjuvant chemoradiotherapy (NACR) treatment, we hypothesized that safe and effective MIE could be performed in this setting.

Materials and Methods

We reviewed our prospective database of patients undergoing MIE for esophageal cancer at our institution between January 2008 and February 2010. We analyzed the association of NACR on perioperative outcomes and compared them with those patients undergoing MIE without NACR. NACR was used in ≥T2 or N+ tumors.

Results

A total of 61 consecutive patients underwent a planned MIE. A complete MIE or hybrid procedure was performed in 58 patients (95%), while 3 patients were unresectable. Median age was 67 years (range 38–85). Anastomoses were performed in the cervical region in 47 patients (81%) while 11 patients had an anastomosis in the right chest. Serious complications included: 3 cervical anastomotic leaks (5%), 2 thoracic duct leaks (4%), 12 pneumonias (21%), 10 atrial fibrillations (18%), and 1 death in a patient not undergoing NACR. NACR was used in 41 patients. There was no significant difference in estimated blood loss (EBL), complications, or negative pathologic margins in patients undergoing NACR with MIE vs. MIE alone (P = NS). Median number of lymph nodes excised and PostOp LOS was 15 and 11 in patients undergoing NACR compared with 13 and 9 in those undergoing MIE alone (P = NS).

Conclusion

MIE is safe following NACR. Excellent results can be achieved with this operation in patients with advanced tumors.

Brooks JA, Kesler KA, Johnson CS, Ciaccia D, Brown JW. Prospective analysis of quality of life after surgical resection for esophageal cancer: preliminary results. J Surg Oncol. 2002;81:185–94.PubMedCrossRef

Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005;242:341–6.

Ku GY, Ilson DH. Role of neoadjuvant therapy for esophageal cancer. Surg Oncol Clin N Am. 2009;18:533–46.PubMedCrossRef

Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterology. 2009;15:4962–8.CrossRef

Roof KS, Coen J, Lynch TJ, Wright C, Fidias P, Willett CG, et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2006;65:1120–8.PubMedCrossRef

DePaula AL, Hashiba K, Ferreira EA, de Paula RA, Grecco E. Laparoscopic transhiatal esophagectomy with esophagogastroplasty. Surg Endosc. 1995;9:681–6.PubMedCrossRef

Swanstrom LL. Minimally invasive surgical approaches to esophageal cancer. J Gastrointest Surg. 2002;6:522–6.PubMedCrossRef

Luketich JD, Alvelo-Rivera M, Buenaventura PO, Christie NA, McCaughan JS, Litle VR, et al. Minimally-invasive esophagectomy: Outcomes in 222 patients. Ann Surg. 2003;238:486–94.PubMed

Rice TW. Esophagectomy is the treatment of choice for high-grade dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2006;101:2177–84.PubMedCrossRef

10.

Orringer MB, Marshall B, Chang AC, Lee J, Pickens A, Lau CL. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246:363–72.PubMedCrossRef

11.

Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, et al. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg. 2007;246:624–8.PubMedCrossRef

12.

Birkmyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–37.CrossRef

13.

Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.PubMedCrossRef

14.

Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.PubMed

15.

Burmeister BH, Smithers BM, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus, a randomized controlled phase III trial. Lancet Oncol. 2005;6:659–68.PubMedCrossRef

16.

Natsugoe S, Okumura HM, Uchikado Y, Uchikado Y, Setoyama T, Yokomakura N, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006;19:468–72.PubMedCrossRef

17.

Urschel JD. Esophagogastrostomy anastomotic leaks complicating esophagectomy—a review. Am J Surg. 1995;169:634–40.PubMedCrossRef

18.

Keller SM, Ryan LM, Coia LR, Dang P, Vaught DJ, et al. High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: results of a phase II study of the Eastern Cooperative Oncology Group. Cancer. 1998;83:1908–16.PubMedCrossRef

19.

Avendano CE, Flume PA, King LB, Reed CE. Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002;73:922–6.PubMedCrossRef

20.

Schilling MK, Eichenberger M, Maurer CA, Sigurdsson G, Büchler MW. Ketoconazole and pulmonary failure after esophagectomy: a prospective clinical trial. Dis Esophagus. 2001;14:37–40.PubMedCrossRef

21.

Nguyen NT, Hinojosa MW, Smith BR, Chang KJ, Gray J, Hoyt D. Minimally invasive esophagectomy: lessons learned from 104 operations. Ann Surg. 2008;248:1081–91.PubMedCrossRef

22.

Palanivelu C, Prakash A, Senthilkumar R, Senthilnathan P, Parthasarathi R, Rajan PS, et al. Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position—experience of 130 patients. J Am Coll Surg. 2006;203:7–16.PubMedCrossRef

23.

Díaz R, Reynes G, Tormo A, de Juan M, Gironés R, Segura A, et al. Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience. Clin Transl Oncol. 2009;11:835–41.PubMedCrossRef

24.

Mak RH, Mamon HJ, Ryan DP, Miyamoto DT, Ancukiewicz M, Kobayashi WK, et al. Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. Dis Esophagus. 2010;23:316–23.PubMedCrossRef

25.

Griffin SM, Shaw IH, Dresner SM. Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: risk factors and management. J Am Coll Surg. 2002;194:285–97.PubMedCrossRef

26.

Rindani R, Martin CJ, Cox MR. Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference? Aust N Z J Surg. 1999;69:187–94.PubMedCrossRef

27.

Kohn GP, Galanko JA, Meyers MO, Feins RH, Farrell TM. National trends in esophageal surgery—are outcomes as good as we believe? J Gastrointest Surg. 2009;13:1900–10.PubMedCrossRef

28.

Khithani A, Jay J, Galanopoulos C, Curtis D, Vo A, Jeyarajah DR. Zero leaks with minimally invasive esophagectomy: a team-based approach. JSLS. 2009;13:542–9.PubMedCrossRef

Title: Minimally Invasive Esophagectomy is Safe and Effective Following Neoadjuvant Chemoradiation Therapy
Authors: Kfir Ben-David, MD
George Rossidis, MD
Robert A. Zlotecki, MD, PhD
Stephen R. Grobmyer, MD
Juan C. Cendan, MD
George A. Sarosi, MD
Steven N. Hochwald, MD
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 12/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1702-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Minimally Invasive Esophagectomy is Safe and Effective Following Neoadjuvant Chemoradiation Therapy

Abstract

Background

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2011

Erratum to: Incidental Papillary Microcarcinoma of the Thyroid—Further Evidence of a Very Low Malignant Potential: A Retrospective Clinicopathological Study With Up to 30 Years of Follow-Up

Incidental Papillary Microcarcinoma of the Thyroid—Further Evidence of a Very Low Malignant Potential: A Retrospective Clinicopathological Study With Up to 30 Years of Follow-Up

Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature

Expression of the Transient Receptor Potential Channel C3 Correlates with a Favorable Prognosis in Patients with Adenocarcinoma of the Lung

Prognostic Significance of Stromal Microinvasion in the Intestinal Type of Ovarian Mucinous Adenocarcinoma

Butylidenephthalide Suppresses Human Telomerase Reverse Transcriptase (TERT) in Human Glioblastomas